Clomiphene (Clomid)- FDA

Opinion Clomiphene (Clomid)- FDA that would

Co-administration of other drugs drug information portal to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as cisapride, astemizole, erythromycin, amiodarone, pimozide and quinidine is contraindicated in patients receiving fluconazole (see Section 4. Anaphylaxis has been reported in rare instances. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities, primarily in patients with serious underlying medical conditions.

In cases of fluconazole-associated hepatoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of the patient has been observed. Fluconazole should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole (see Section 4.

Patients have rarely developed exfoliative cutaneous reactions, e. Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. AIDS patients are more prone to the development of serious cutaneous reactions to many drugs. If a rash that is attributable to fluconazole develops in a patient treated for a superficial fungal infection, fluconazole should be discontinued.

Some azoles, including fluconazole, have been associated with prolongation Clomiphene (Clomid)- FDA the QT interval on the electrocardiogram.

Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (Ikr). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4 (see Section 4. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking fluconazole.

These reports included seriously ill patients with multiple confounding risk factors, such as structural Clomiphene (Clomid)- FDA disease, electrolyte abnormalities and concomitant medications that may have been contributory. Patients with hypokaelaemia and advanced cardiac failure are at an increased risk for the occurrence of life-threatening ventricular arrhythmias and torsades de pointes. Fluconazole should be Clomiphene (Clomid)- FDA with caution to patients with these potentially proarrhythmic conditions (see Section 4.

In rare cases, as with other azoles, anaphylaxis has been reported. Fluconazole is a potent CYP2C9 and CYP2C19 inhibitor and a moderate CYP3A4 inhibitor.

Fluconazole-treated patients who are concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9, CYP2C19 and CYP3A4 should be monitored (see Section 4. Fluconazole Sandoz capsules contain lactose monohydrate and should not be given to patients with rare hereditary problems Clomiphene (Clomid)- FDA galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

Ketoconazole is known to cause adrenal insufficiency. Cases of adrenal insufficiency were reported in patients receiving fluconazole. Adrenal insufficiency relating to concomitant treatment with prednisone is described, see Section 4. Fluconazole has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions.

Clomiphene (Clomid)- FDA cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Dosage should be adjusted for elderly patients with renal impairment (see Section Clomiphene (Clomid)- FDA. Fluconazole is an inhibitor of the cytochrome P450 system, particularly the CYP2C Clomiphene (Clomid)- FDA to a lesser extent the CYP3A isoforms.

There are possibilities that other drugs may affect the metabolism of fluconazole and that fluconazole may affect the metabolism of other drugs. In vitro studies conducted in human hepatic microsomes demonstrate that the extent of inhibition Clomiphene (Clomid)- FDA CYP3A isoforms is lowest with fluconazole, when compared with ketoconazole and itraconazole. Clinically or potentially significant drug interactions have been observed between fluconazole and the following agents: short acting benzodiazepines, cisapride, coumarin-type anticoagulants, ciclosporin, hydrochlorothiazide, oral hypoglycaemics, phenytoin, rifampicin, rifabutin, tacrolimus and theophylline.

These are Stavzor (Valproic Acid)- FDA in greater detail below. The drug-drug interactions described below include Tapentadol Immediate-Release Oral Tablets (Nucynta)- FDA interactions mediated through effects on P450 metabolism and interactions mediated through other mechanisms.

Effects of other medicinal products on fluconazole. The exposure to fluconazole is significantly increased by the concomitant administration of the following agent: Hydrochlorothiazide. Overall, the plasma concentrations of fluconazole were approximately 3. The exposure to fluconazole is significantly Clomiphene (Clomid)- FDA by the concomitant administration of the following agent. Depending on clinical circumstances, an increase of the dose of fluconazole should be considered when it is administered with rifampicin.



There are no comments on this post...